ASH25 Highlight – Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”ASH25 Highlight – Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Important new insights from a post-hoc analysis of the RENOVE randomized trial, evaluating safety during extended treatment (after ≥6 months of full-dose therapy) with apixaban or rivaroxaban by Prof Francis COUTURAUD
Key Findings (5-year outcomes):
• Clinically relevant bleeding (CRB): Similar between drugs at both full and reduced doses.
• Major bleeding: No significant differences across subgroups.
• Recurrent VTE: Low and comparable with both agents.
• Dose reduction: Consistently lowered CRB risk for both apixaban and rivaroxaban.
Takeaway:
Unlike early-treatment data where rivaroxaban shows higher bleeding risk, during extended therapy the safety profiles of apixaban and rivaroxaban appear equivalent. More trials are needed.”
Stay updated with Hemostasis Today.
-
Sep 8, 2026, 15:16Eric Topol: Anti-H2B Autoantibodies Linked to Aortic Calcification in Atherosclerosis
-
Sep 8, 2026, 15:20David Walcott: The History of SCD Scientific Progress and Patient Advocacy
-
Sep 8, 2026, 15:19Nilesh Jethwa: Reported Adverse Events and Safety Signals With Ofatumumab
-
Sep 8, 2026, 15:18Sanish Babu: Dengue Management – Watch the Hematocrit, Not Just the Platelets
-
Sep 8, 2026, 15:17Joel Gator: Vitamin K Is Not a Vaccine
-
Sep 8, 2026, 15:05Udhayvir Grewal։ Bridging the Gap in Chemotherapy-Induced Thrombocytopenia
-
Sep 8, 2026, 14:58Manuel Monreal: DOACs Show Advantages Over VKAs in DVT Patients
-
Sep 8, 2026, 14:43Kemal Karaagac: LAAC vs DOACs in Atrial Fibrillation
-
Sep 8, 2026, 14:43Talat Kılıç: Can Heparin Be Used Again After HIT?